drial function (Keller et aI., 1998) , or the delocalization of intracellular iron (Oubidar et aI., 1996) . Neuroprotection by antioxidants is, therefore, a promising therapeutic strategy for the treatment of chronic neurodegenerative diseases and stroke (Hall, 1993; Wolz et aI., 1996) .
Estrogens show antioxidative activities because of the phenolic structure in the A ring of these steroids (Behl et aI., 1997; Subbiah et aI., 1993) . Increasing data support the view that estrogens may be useful for the therapy of disorders that are linked to ROS-mediated cellular dam age, including cardiovascular diseases (Keany et aI., 1994; Schwartz et aI., 1995) and Alzheimer's disease (Henderson et aI., 1994; Tang et aI., 1996) . Estrogens could be useful in preventing or delaying the onset of Alzheimer's disease in postmenopausal women (Hender son et aI., 1994; Paganini-Hill and Henderson, 1996; Simpkins et aI., 1997) . 17�-Estradiol was found to re duce low-density lipoprotein oxidation, suggesting a mechanism against atherosclerosis by preserving endo thelium-dependent vascular relaxation (Keaney et aI., 1994) . Increasing evidence also suggests that estrogens improve the outcome after cerebral ischemia in rodents (Alkayed et aI., 1998; Dubal et aI., 1998; Pelligrino et aI., 1998; Toung et aI., 1998) . These studies mainly investi gated effects of the estrogen 17f3-estradiol at physiologic doses on the cerebral infarction after a prolonged pre treatment.
In vitro, estrogens have been shown to protect neurons against insults induced by glutamate, glucose depriva tion, iron, and f3-amyloid (Behl et aI., 1995; Goodman et aI., 1996) . Estrogens might affect neuronal damage by several mechanisms, such as the enhanced synthesis of neurotrophic factors (Singh et aI., 1995) , inhibition of N-methyl-o-aspartate receptors (Weaver et aI., 1997) , or through anti oxidative activities (Behl et aI., 1995 (Behl et aI., , 1997 Goodman et aI., 1996) . In most of the in vitro studies, micromolar concentrations of estrogens were used to demonstrate their neuroprotective effect against oxida tive stress. Thus, it remained to be clarified whether es trogen derivatives also protect neurons against oxidative damage at nanomolar concentrations in vitro and then through estrogen receptor stimulation, or rather as a re sult of their antioxidative properties, as suggested by Behl et ai. (1997) . In the current study, we measured the effects of the 3-0H steroids 17f3-estradiol and 2-0H estradiol on the intracellular ROS level and the oxidative damage in primary chick neurons after incubation with FeS04. Moreover, we evaluated whether the neuropro tective effects� of these estrogens in vitro also could be verified in a mouse model of permanent focal cerebral ischemia through acute administration of low pharmaco logic doses of estrogen derivatives.
MATERIALS AND METHODS

Animals
Male NMRI mice (Charles River, Sulzfeld, Germany) were used for ischemia experiments. The animals were maintained under controlled light and environmental conditions (12: 12 hour dark-light cycle, 23° ± 1°C, 55% relative humidity) and had free access to food (Altromin, Lage, Germany) and water.
Permanent focal cerebral ischemia in mice
Permanent middle cerebral artery (MCA) occlusion was per formed in male NMRI mice (1 2 to 17 animals per group) ac cording to the method described by Welsh et al. (1987) . Briefly, after the mice were anesthetized with tribromoethanol (600 mg/kg intraperitoneally), a small hole was drilled in the skull to expose the middle cerebral artery. The stem of the middle cerebral artery and both branches were permanently occluded by electrocoagulation. Body temperature was maintained at 37° ± 1°C with a heating lamp during the surgical procedure. Af terward, the mice were kept at an environmental temperature of 30°C for 2 hours after middle cerebral artery occlusion. For histologic evaluation, the mice were anesthetized again with tribromoethanol and perfused intraperitoneally with a 1.5% so lution of neutral red (0.5 mL) 2 days after middle cerebral artery occlusion. The brains were removed and stored in a fixative (4% formalin in phosphate buffer solution, pH 7.4) for 24 hours. As described previously, in this model of focal ce rebral ischemia in mice, only cortical tissue was found to be infarcted, and furthermore, the infarct volume correlated with the infarct surface (Backhau13 et a!., 1992; Culmsee et a!., J Cereb Blood Flow Metab, Vol. 19. No. Ii, 1999 1998). The tissue on the brain surface unstained by neutral red was determined as infarcted surface area (in square millime ters) by means of an image analyzing system (Kontron, Eching, Germany) according to Backhauss et al. (1992) . Mice received 1713-estradiol (0.03 to 30 mg/kg) and 2-0H-estradiol (0.0003 to 30 mg/kg) subcutaneously 24 hours before induction of perma nent focal ischemia. A second dose of the estrogens was ad ministered intraperitoneally 3 hours before MCA occlusion. To cause neuronal injury, the cells were incubated with lOO fLmollL FeS04 for 24 hours in serum-free DMEM. Afterward, the percentage of damaged neurons was calculated by the trypan blue exclusion method.
Determination of mitochondrial ROS production
Mitochondrial ROS production was measured as described before (Ahlemeyer et a!., 1998; Ravati et al., 1999) . Briefly, ROS production was monitored 3 hours after incubation with 
Statistics
All values were calculated as means ± SO. One-way analysis of variance combined with Scheffe's test or Duncan's analysis were used for in vitro and in vivo data, respectively.
RESULTS
Effect of 17J3-estradiol and 2-0H-estradiol on Fe 2 + -induced neuronal damage Neuronal damage was induced by an incubation with 100 /-1mollL FeS04 for 24 hours to a level of 42.8 ± 4.0% trypan blue-stained neurons compared with 13.3 ± 3.9% in sister control cultures. Neurotoxicity induced by Fe 2+ was significantly attenuated by 17�-estradiol (1 to 10 /-1mollL) (Fig. IA) . In a second series of experiments, concentrations of 0.0 1 to 1 /-1mollL 2-0H-estradiol re duced the percentage of damaged neurons from 43% in Fe 2+ -treated cultures to a maximum of 22%. In contrast, concentrations of 100 /-1mollL 17�-estradiol showed no neuroprotective effect, and 10 /-1mollL 2-0H-estradiol markedly enhanced the Fe 2+ -induced neuronal damage (Fig. 1) . Tamoxifen (l /-1mollL) added simultaneously with the estrogens did not block the effects of 17� estradiol and 2-0H-estradiol against neuronal damage (Fig. 1) . Tamoxifen (l /-1moI/L), l7�-estradiol (0.00 1 to 100 /-1moI/L), and 2-0H-estradiol (0.00 1 to 1 /-1mollL) alone did not influence neuronal viability, whereas 2-0H-estradiol concentrations of 10 /-1mol/L and higher markedly enhanced the percentage of trypan blue stained neurons.
Radical scavenging properties of the estrogens
17J3-estradiol and 2-0H-estradiol
To quantify the production of ROS, a fluorescent mi croscope combined with a digital video imaging system was used, which allowed a measurement within single neurons. After exposing the cultures to 100 /-1mollL Fe 2+ for 3 hours, there was an increase in fluorescence from 6 fluorescence units in controls to 47 fluorescence units . c (Fig. 2) . Both 17�-estradiol and 2-0H-estradiol de creased the Fe 2+ -induced production of intracellular ROS fluorescence in a concentration-dependent manner. The lowest concentration of 17�-estradiol required to signifi cantly diminish ROS fluorescence was 1 /-1mollL ( Figs. 2  and 3A) . A significant reduction of ROS fluorescence by 2-0H-estradiol was achieved already at 0.0 1 /-1mollL ( Figs. 2 and 3B ). Tamoxifen (l /-1mollL) did not block the effect of the estrogens on the production of ROS after Fe 2+ treatment. Tamoxifen (l /-1mollL), 17�-estradiol (0.00 1 to 10 /-1moI/L), or 2-0H-estradiol (0.00 1 to 10 /-1moIlL) alone did not affect ROS fluorescence com pared with controls (data not shown).
Focal cerebral ischemia in mice
Four series of ischemia experiments were performed in mice to test the protective capacities of 17�-estradiol and 2-0H-estradiol against brain damage caused by per manent MCA occlusion. Both steroids investigated were able to reduce the ischemia-induced brain damage in the model of focal cerebral ischemia in mice. 17�-Estradiol (0.3 to 3 mg/kg) significantly reduced the infarct area on the mouse brain surface ( Table 1) . Doses of 17� estradiol lower than 0.3 mg/kg showed no effect. 2-0H Estradiol reduced the infarct area at doses of 0.03 to 30 mg/kg (Table 1 ). The lowest effective dose of 2-0H estradiol was determined at 0.03 mg/kg, although in one series of experiments, this steroid protected brain tissue from ischemic damage already at 0.003 mg/kg (data not shown). In the four series of ischemia experiments per formed in the current study, 8 of 55 vehicle-treated mice died after MCA occlusion. In contrast, only 4 of 57 mice and 4 of 122 animals died in the groups treated with l7�-estradiol and 2-0H-estradiol, respectively.
DISCUSSION
In the current study, we demonstrated a protective ac tivity of the estrogens 17�-estradiol and 2-0H-estradiol against iron-induced neuronal cell death in primary cul tures of chick embryonic neurons. In addition, we showed that the suppression of mitochondrial ROS pro duction and the neuroprotective effect of these estrogens were mediated receptor-independently through their an tioxidative activity. These data are consistent with pre vious studies showing that, because of their anti oxidative capacities, estrogens suppress iron-induced lipid peroxi dation of liver microsomes (Ruiz-Larrea et aI., 1994), reduce oxidative damage in rat cortical synaptosomes (Keller et aI., 1997) , and preserve vascular relaxation resulting from reduced oxidation of low-density lipopro tein (Keaney et aI., 1994) . In most of the previous stud ies, micromolar concentrations of the estrogens were used to demonstrate neuroprotection against trophic fac tor withdrawal and cytotoxic stimuli, including �-amy loid, iron, glutamate, or hydrogen peroxide (Behl et aI., 1997; Goodman et aI., 1996; Mattson et aI., 1997) . The concentrations used in earlier investigations were thus always higher than physiologic, nanomolar blood levels. From these in vitro experiments, the capacity of estro gens to scavenge cytotoxic free radicals at high concen trations was suggested as the underlying mechanism of neuroprotection. By measuring neuronal damage and production of ROS after exposure to iron, we demon strate that 2-0H-estradiol is capable of protecting neu rons from oxidative stress already at nanomolar concen trations (10 nmollL). In contrast, 17�-estradiol showed antioxidative effects only if added to the cell culture medium at micromolar concentrations (l to 10 /JvmoIlL), which is in line with previous reports. The concentrations of both estrogens required for protection against iron induced oxidative stress in vitro were in the order of magnitude expected to activate their receptors (10 to 1000 nmollL). However, the estrogen receptor antagonist tamoxifen influenced neither the neuroprotective effect nor the antioxidati ve capacity of the estrogens, indicating that the effects were mediated by the inherent antioxidant properties of the steroids investigated. This finding con firms the results of a structure-activity study showing that the hydroxyl group at the C3 position of the steroid A ring confers the neuroprotective antioxidant activity of estrogens (Behl et aI., 1997) .
Although the precise mechanism of action has yet to be defined, tamoxifen is widely used to inhibit estradiol binding to the estrogen receptor. Under our experimental conditions, tamoxifen alone or in combination with es trogens did not affect cell survival or the cellular con centration of free radicals. Evidence shows that neuro protection by estrogens does not necessarily depend on activation of estrogen receptors because higher concen trations than expected for estrogen receptor stimulation Animals received 2 injections of 17�-estradiol or 2-0H-estradiol 24h (subcutaneously) and 3 h (intraperitoneally) before middle artery occlusion. Fourty-eight hours after surgery 1.5% solution of neuL'a1 red was injected intraperitoneally to stain the brain tissue. The unstained area on the brain surface was measured as the infact area (mm 2 ) by means of an image analyzing system. Values are given as mean ± SD.
Different from vehicle-treated control: *p < 0.05, t P < 0.01, and + P < 0.001 by analysis of variance with subsequent Duncan's test.
were needed to obtain neuroprotective effects in previous studies (Behl et aI., 1995 (Behl et aI., , 1997 Goodman et aI., 1996) . In a neuroblastoma cell line, 17a-estradiol, which does not bind to the estrogen receptor, prevented cell death induced by serum deprivation similar to 1713-estradiol (Green et aI., 1997) . Furthermore, 1713-estradiol pre vented iron-induced membrane oxidation independent of estrogen receptor-mediated transcriptional activation in a synaptosome preparation (Keller et aI., 1997) . On the other hand, these authors did not exclude the stimulation of membrane receptors by 1713-estradiol at nanomolar concentrations as a possible mechanism of protection. Furthermore, estrogen receptor-mediated neuroprotec tion was suggested to include upregulation of neuro trophins such as nerve growth factor (Singh et aI., 1995) and the high-affinity tyrosine ki nase receptor (Gibbs, 1998) . 1713-Estradiol protected human neuroblastoma cells against l3-amyloid toxicity already at nanomolar concentrations, ameliorating both lipid peroxidation and persistent lactate production (Green et aI., 1996; Gridley et aI., 1997) . Although neuronal death may be prevented by estrogens through receptor-dependent and receptor independent mechanisms, we suggest from our data that estrogens reduce oxidative stress independent from bind ing to their receptors.
In addition,f we were able to demonstrate that 1713estradiol and 2-0H-estradiol protected male mice from ischemic brain damage at doses as low as 0.3 mg/kg and 0.03 mglkg, respectively. Our finding indicates that the neuroprotective effects observed in cultured neurons also were relevant for estrogen effects obtained in vivo. Strong evidence demonstrates that scavenging free radi cals exerts protection of brain tissue against damage caused by MCA occlusion (Muller et aI., 1994; Wolz and Krieglstein, 1996) . Furthermore, recently published data show that gender differences in response to focal cere bral ischemia in rats result from the different estrogen levels in female versus male animals (Alkayed et aI., 1998; Zhang et aI., 1998) . In these studies, female rats showed smaller infarct sizes and higher CBF than male animals after transient MCA occlusion. Moreover, the loss of female sex steroids in ovarectomized female rats was demonstrated to increase the infarct volume com pared with control female animals (Hum et aI., 1998) . Chronically administered 1713-estradiol abolished the in creased susceptibility to ischemic brain damage in ovar ectomized rats (Zhang et aI., 1998 ). In the current study, we demonstrated that 1713-estradiol protected brain tis sue from ischemic damage in male mice when adminis tration was started 24 hours before ischemia. Moreover, we demonstrated that 2-0H-estradiol reduced the isch emic brain damage after MCA occlusion already at doses 10 times lower than the 1713-estradiol doses needed for protection. A similar finding was observed in vitro as far as 2-0H-estradiol reduced intracellular ROS concentra-J Cereb Blood Flow Metab. Vol. 19. No. II, 1999 tion and neuronal cell death at concentrations 100 times lower than that of 1713-estradioI. Our results confirm the view that the structure-related neuroprotective effect of estrogens against oxidative stress in vitro (Behl et aI., 1997 ) also helps to predict cerebroprotective activities in vivo. Under our experimental conditions, pharmacologic doses of the estrogens were necessary to achieve protec tion against ischemic brain damage. This finding sug gests that, also in vivo, the antioxidative properties of the estrogens led to neuroprotection rather than a receptor mediated mechanism.
In conclusion, we demonstrated that neuroprotection against oxidative damage by estrogens was most likely caused by the antioxidant properties of these steroids. The reduced amount of reactive oxygen species in vitro occurred at concentrations that were relevant for the ce rebroprotective activities of the estrogens observed in the mouse model of focal cerebral ischemia. Thus, estrogens, and especially the catechol estrogen 2-0H-estradiol, may prove efficacious as neuroprotectants in the acute therapy of ischemic stroke.
